12 July 2021 in Revista Neurociências
NBNathalia Clemente Baracho
Nathalia Clemente Baracho
Introduction. Alzheimer's disease (AD) is a neurodegenerative disorder with a poor prognosis and no cure that affects millions of people worldwide. Medicines today in clinical studies try to investigate possible therapeutic effects that progress or stop the disease. Objective. This review is necessary to create a current panorama in 2021, describing the main pathways under study to inhibit important pathways of disease progression, such as pathways cholinergic system and ROCK inhibitors, as well as new perspectives of treatment with possible combination of drugs, to decrease neuroinflammation and change the course of the disease. Method. Reviewed ClinicalTrials.gov as of January 19, 2021, identified all trials of pharmacologic agents currently being developed for treatment of AD in phase 3 of clinical study, thus obtaining a global panorama to curb this devastating disease, creating better perspectives on the treatment of AD. Results. Different drugs (n = 25) were divided by types of targets of neurophysiological pathways (amyloid inhibitor; tau inhibitor; neurotransmitter receptors; non-steroidal anti-inflammatory drugs (NSAIDs), mitochondria and metabolic functions; synaptic plasticity). Conclusions. Advances in clinical trials bring hope and new avenues as targets for AD treatment are encouraged and show promise for new lines of treatment. New studies with more therapeutic combinations that change the course of the disease should be encouraged.
1 December 2025 in American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
Afferent nerves from the renal pelvis contribute to the modulation of renal sympathetic nerve activity (rSNA) in response to low-dose furosemide intravenous administration. Capsaicin-sensitive C-fiber afferents, located in the renal pelvis, selectively alter the pattern of sympathetic outflow to the kidneys. Intrapelvic low-dose furosemide increases rSNA without affecting splanchnic sympathetic nerve activity (sSNA).
25 May 2026 in SSRN Electronic Journal
Proteolytic reaction networks play vital roles in key biological processes like coagulation cascades, complement activation, and inflammatory signaling. However, accurately measuring the protease kinetics within these networks can be challenging. Traditional approaches often rely on measuring only the initial linear phase of the reaction, which can require large amounts of reagents and introduce variability due to subjective selection of early time points. This can reduce reproducibility, particularly when substrate concentrations decrease rapidly during the reaction. To overcome these challenges, we applied a mathematical framework based on the explicit Schnell–Mendoza solution of the integrated Michaelis–Menten equation. By using the Lambert function, this approach allows direct nonlinear fitting of entire reaction time courses without the need for complex root-finding or selecting initial velocities. We also incorporated the Goličnik analytical approximation as a simple and highly accurate alternative. Using representative coagulation proteases including human α-thrombin, factor XIa, and plasma kallikrein, we demonstrated that this method reliably estimates kinetic parameters ( and ), while reducing experimental effort, improving reproducibility, and enhancing analytical transparency. Importantly, the method remains robust under conditions where traditional initial-rate analyses are compromised by substrate depletion or poorly defined linear regions. Overall, this progress-curve approach provides a practical and efficient strategy for studying dynamical proteolytic systems. Beyond coagulation enzymes, the framework may be broadly applicable to enzyme network analysis, assay development, diagnostics, and molecular engineering in complex biological systems.
6 November 2026 in Cellular and Molecular Bioengineering